This notable work showed that enhancing JPH2 expression using a gene-therapy approach after the onset of the disease prevented the progression of heart failure, thereby demonstrating that JPH2 could be a therapeutic target for the treatment of cardiomyopathies associated with T-tubule deterioration. Here, JPH2 is linked to cardiomyopathy.